|
Jul 25
|
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
|
|
Jun 18
|
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
|
|
May 28
|
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
|
|
May 24
|
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
|
|
Jan 12
|
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
|
|
Dec 19
|
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
|
|
Dec 11
|
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
|
|
Dec 10
|
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
|
|
Nov 27
|
Innate Pharma to Host Virtual KOL Event on Lacutamab
|
|
Jun 26
|
Innate Pharma: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
|
|
Jun 26
|
First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
|